Upscaling production of CollPlant’s regenerative breast implants using our bioprinting technologies

CollPlant and CELLINK will explore the use of CELLINK’s next-generation high throughput extrusion bioprinters for the future commercial production of CollPlant’s regenerative breast implants, addressing a $2.8 Bn market

Today, CELLINK and CollPlant Biotechnologies, a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, announced that we have signed a collaboration agreement. Under this collaboration, CELLINK’s high-throughput, multi-material extrusion bioprinter will be explored for the development of large-scale production of CollPlant’s 3D bioprinted regenerative breast implants, addressing a current market size of $2.8 billion, with 2.2 million procedures performed annually worldwide.

CollPlant has successfully produced prototypes of 3D bioprinted implants designed to regenerate breast tissue, and is currently evaluating these implants in a series of preclinical studies. Comprised of CollPlant’s rhCollagen and other biological components, the regenerative implants aim to overcome the challenges of existing breast procedures that use silicone implants or autologous fat tissue transfer. In contrast with current approaches, CollPlant’s regenerative implants are designed to degrade over time to be replaced by new, naturally grown breast tissue.

We at CELLINK are well positioned to support CollPlant in their large-scale bioprinting production process through the use of our printers and technical expertise.

“We are thrilled to be working with a partner who shares our values and passion to create the future of health. We look forward to making an impact in the breast implant industry but also to develop a long-lasting relationship with CollPlant characterized by advancements in the wider field of tissue engineering and regenerative medicine” said Cecilia Edebo, CEO CELLINK.

“We are very pleased to enter into the collaboration with CELLINK, a recognized leader in development of 3D bioprinting solutions for the life-science industry,” said CollPlant’s CEO, Yehiel Tal. “We believe CELLINK’s high throughput bioprinters and biofabrication expertise will help us move toward the successful commercialization of our technology and to deliver a much-needed solution to patients around the world”.

Read the full release here.

More News